11.10.2021

Additional Series B funding announcement

We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli Investitori having committed funds of £0.6m ($1m). This financing will be used to further advance the candidates in NeoPhore’s drug discovery pipeline.

More news

31.08.2021

Neophore appoints Stephen Over as Chief Financial Officer

We are delighted to announce the appointment of Stephen Over as the Company's Chief Financial Officer and new member of the Executive team. Stephen…

22.04.2021

NeoPhore Announces Scientific Founder Dr Alberto Bardelli Awarded €2.5 million European Research Council (ERC) Advanced Grant

22 April, Cambridge, UK – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced that its scientific founder, Dr A…

09.03.2021

NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline

Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management 9 March 2021, Cambridge, UK – NeoPhore Limited, a s…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990